The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1426
ISSUE1426
September 30, 2013
Radium-223 (Xofigo) for Prostate Cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Radium-223 (Xofigo) for Prostate Cancer
September 30, 2013 (Issue: 1426)
Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic
drug, has been approved by the FDA for
intravenous treatment of castration-resistant prostate
cancer with symptomatic bone metastases and no
known visceral metastatic disease.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.